Hemoadsorption by extracorporeal cytokine adsorption therapy (CytoSorb ® ) in the management of septic shock: A retrospective observational study

Abstract

Introduction:

Sepsis results in immunologic disturbances with the release of various inflammatory mediators such as cytokines. Cytokines can damage the cells, and the continuous release of inflammatory mediators leads to severely impaired immunity. Therefore, the reduction in cytokine levels by hemoadsorption represents a new concept for blood purification. CytoSorb^® as a hemoadsorption device is a detoxification system, which aims to decrease the cytokines levels. This study was conducted to understand any beneficial effects of CytoSorb^® therapy in septic patients.

Methodology:

This was a retrospective and observational study, approved by the scientific and ethics committee of Max Super Specialty Hospital, Patparganj, Delhi, India and conducted in compliance with current International Council for Harmonization, Good Clinical Practice, Schedule Y, and Indian Council of Medical Research guidelines. Subjects of either gender (age > 18 year) were included in the study. The data were presented as mean ± standard deviation and categorical as frequency and percentage (%). A p value less than 0.05 (p < 0.05) was considered to be statistically significant.

Results:

A total number of 36 patients were included in the study. Majority of the patients were male with mean age (56.36 ± 14.83). After therapy, procalcitonin and total leucocyte count levels decreased within 24 h. Post therapy, sepsis-related organ failure assessment (SOFA) score of Day (D)1, D2, and D3 reduced to 10.4 ± 3.63, 8.7 ± 4.02, and 7.8 ± 3.67, respectively. The Acute Physiology and Chronic Health Evaluation (APACHE) II score and predicted mortality were lower in the survivor group as compared to the non-survivor group.

Conclusion:

Hemoadsorption using the extracorporeal adsorption device (CytoSorb^®) might be an effective rescue therapy in stabilizing septic shock patients.

Keywords

Hemoadsorption CytoSorb host response fluid resuscitation sepsis-related organ failure assessment score Acute Physiology and Chronic Health Evaluation II score

Get full access to this article

View all access options for this article.

References

Tsertsvadze

Royle

Seedat

, et al. Community-onset sepsis and its public health burden: a systematic review. Syst Rev 2016; 5(1): 81.

Spronk

Ince

Gardien

, et al. Nitroglycerin in septic shock after intravascular volume resuscitation. Lancet 2002; 360(9343): 1395–1396.

Singer

Deutschman

Seymour

, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315(8): 801–810.

Annane

Aegerter

Jars-Guincestre

, et al. Current epidemiology of septic shock: the CUB-Réa Network. Am J Respir Crit Care Med 2003; 168(2): 165–172.

Rossaint

Zarbock

. Pathogenesis of multiple organ failure in sepsis. Crit Rev Immunol 2015; 35(4): 277–291.

Tetta

Bellomo

Inguaggiato

, et al. Endotoxin and cytokine removal in sepsis. Ther Apher 2002; 6(2): 109–115.

Rimmelé

Kellum

. Clinical review: blood purification for sepsis. Crit Care 2011; 15(1): 205.

Wiegele

Krenn

. CytoSorb™ in a patient with legionella pneumonia-associated rhabdomyolysis: a case report. ASAIO J 2015; 61(3): e14–e16.

Angus

Linde-Zwirble

Lidicker

, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7): 1303–1310.

10.

Kogelmann

Jarczak

Scheller

, et al. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care 2017; 21(1): 74.

11.

Hetz

Berger

Recknagel

, et al. Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs 2014; 37(5): 422–426.

12.

Kellum

Song

Venkataraman

. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-κB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004; 32(3): 801–805.

13.

Trager

Fritzler

Fischer

, et al. Treatment of post-cardiopulmonary bypass SIRS by hemoadsorption: a case series. Int J Artif Organs 2016; 39(3): 141–146.

14.

Frimmel

Schipper

Henschel

, et al. First description of single-pass albumin dialysis combined with cytokine adsorption in fulminant liver failure and hemophagocytic syndrome resulting from generalized herpes simplex virus 1 infection. Liver Transpl 2014; 20(12): 1523–1524.

15.

Suefke

Sayk

Nitschke

. Hemoadsorption in infection-associated rhabdomyolysis. Ther Apher Dial 2016; 20(5): 531–533.

16.

van der Linde

Grootendorst

. First case of toxic shock treated with haemoadsorption by CytoSorb^® in the Netherlands. Neth J Crit Care 2016; 24(2): 27–29.

17.

Peng

Z-Y

Carter

Kellum

. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 2008; 36(5): 1573–1577.

18.

David

Thamm

Schmidt

, et al. Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient. J Intensive Care 2017; 5: 12.

19.

Mitzner

Gloger

Henschel

, et al. Improvement of hemodynamic and inflammatory parameters by combined hemoadsorption and hemodiafiltration in septic shock: a case report. Blood Purif 2013; 35(4): 314–315.

20.

Friesecke

Stecher

S-S

Gross

, et al. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs 2017; 20(3): 252–259.

21.

Schädler

Porzelius

Jörres

, et al. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. Crit Care 2013; 17(2): P62.

22.

Reinhart

Bauer

Riedemann

, et al. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev 2012; 25(4): 609–634.

23.

Bruenger

Kizner

Weile

, et al. First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. Int J Artif Organs 2015; 38(2): 113–116.

24.

Hinz

Jauch

Noky

, et al. CytoSorb, a novel therapeutic approach for patients with septic shock: a case report. Int J Artif Organs 2015; 38(8): 461–464.